With a 10% tariff making Chinese products costlier, US importers may turn to Indian companies as cost-effective alternatives.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

U.S. CPI report sent traders scrambling to further recalibrate their Fed rate cut expectations. Read more here.

A new survey from the ABPI has revealed a surge in apprenticeships, placements and global research collaborations in the UK ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

The grants have been the source of new treatments for cancer, heart disease, diabetes, strokes and H.I.V.; wonder drugs like ...

India's pharmaceutical industry is set to grow significantly, with its share in the global market expected to reach 5% by 2030. Currently valued at USD 55 billion, the market is projected to hit up to ...